What is Antabio?
Antabio is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of novel antibacterial treatments. The company focuses on high-priority pathogens identified by the CDC and WHO, specifically targeting life-threatening respiratory infections such as carbapenem-resistant nosocomial pneumonia. By developing differentiated therapeutic candidates like MEM-ANT3310, Antabio addresses the urgent medical need for effective interventions against resistant bacterial strains, including Acinetobacter baumannii and Enterobacterales. Its market position is defined by a rigorous scientific focus on chronic pulmonary diseases and hospital-acquired infections, positioning the firm as a critical player in the global fight against antimicrobial resistance.
How much funding has Antabio raised?
Antabio has raised a total of $38.3M across 3 funding rounds:
Share Placement
$2.8M
Series A
$8.6M
Series B
$26.9M
Share Placement (2017): $2.8M with participation from Carb-X
Series A (2017): $8.6M led by Galia Gestion, IRDI SORIDEC Gestion, and iXO Private Equity
Series B (2023): $26.9M supported by The AMR Action Fund and BNP Paribas Développement
Key Investors in Antabio
The AMR Action Fund
The AMR Action Fund is a specialized investment vehicle dedicated to overcoming technical and financial barriers in antibiotic development to combat superbugs.
BNP Paribas Développement
A subsidiary of the BNP Paribas banking group, this firm provides long-term capital to support the growth of innovative SMEs and high-potential startups.
Carb-X
Carb-X is a global non-profit partnership that accelerates antibacterial innovation by funding early-stage development of life-saving products.
What's next for Antabio?
With the recent capital infusion, Antabio is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The strategic backing from specialized funds and institutional investors provides the necessary runway to advance its lead programs through pivotal trials. Future growth will likely center on scaling manufacturing processes and navigating regulatory pathways to bring these essential therapies to market. As the company continues to mature, its focus will remain on establishing a sustainable innovation ecosystem that addresses the evolving challenges of drug-resistant infections, ultimately aiming to improve patient outcomes in critical care settings worldwide.
See full Antabio company page
